The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The brief provides a quick explainer of the prescription drug provisions in legislative text released by the Senate Finance Committee to be included in a forthcoming reconciliation bill and presents new estimates on how many Medicare beneficiaries could be helped by those provisions.
On May 23, 2022, a panel of experts joined series moderator Larry Levitt in a 45-minute discussion exploring the drivers of rising drug prices and potential administrative actions to address them.
This brief provides an overview of the tele-PrEP landscape, including how PrEP services (e.g., consults, lab work, prescribing, and monitoring) are provided and factors that facilitate its provision as well as barriers that remain. It is based on in-depth interviews with representatives from the major national telehealth companies providing tele-PrEP and other select tele-PrEP programs.
In 2020, only 25% of people who could benefit from pre-exposure prophylaxis (PrEP), a medication that reduces the risk of acquiring HIV, were prescribed it. Using telehealth to provide PrEP, “tele-PrEP,” is a new approach that shows potential for expanding access to PrEP use in the United States that predates the COVID-19 pandemic.
Against the backdrop of public concern about inflation and rising gas prices, proposals to lower what people pay out-of-pocket for drugs tops the public’s list of health care priorities for Congress, a new KFF Health Tracking Poll finds. Most (55%) of the public say inflation is the biggest problem facing the country.
This poll finds the public's health care priorities for Congress focus on reducing out-of-pocket costs, and concerns over inflation and the economy are top of mind as voters begin to think about the November midterm elections. The poll also examines views of the ACA and nursing homes.
This analysis of insurance claims data finds that Congressional proposals to set a $35 per month cap on what people pay out of pocket for insulin would provide financial relief to at least 1 out of 5 insulin users with different types of private health insurance.
In the face of rising prescription drug costs, a large majority of the public supports federal efforts to lower drug spending. Policymakers are considering several proposals that would lower prescription drug costs. To better understand the potential out-of-pocket cost exposure that Medicare beneficiaries may face for Part B drugs, which are typically administered by physicians and other health care providers, we analyzed cost-sharing liability for these drugs in traditional Medicare and cost-sharing requirements in Medicare Advantage plans.
Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.
This chart collection examines what we know about prescription drug spending and use in the U.S. and comparably large and wealthy countries, using data from the Organization for Economic Cooperation and Development (OECD).
© 2026 KFF